Bioreliance
Bioreliance, a prominent name in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1997, the company has established itself as a leader in providing comprehensive biomanufacturing solutions, including cell line development, viral safety testing, and bioprocessing services. Bioreliance is renowned for its innovative approach to quality control and regulatory compliance, ensuring that its clients meet stringent industry standards. With a strong focus on customisation and client collaboration, the company has achieved significant milestones, including numerous successful partnerships with major pharmaceutical firms. As a trusted partner in the biopharmaceutical sector, Bioreliance continues to enhance its market position through cutting-edge technologies and a commitment to excellence in service delivery.
DitchCarbon Score
How does Bioreliance's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bioreliance's score of 6 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bioreliance's reported carbon emissions
Bioreliance's carbon emissions data reveals a comprehensive overview of their greenhouse gas output, with the most recent figures from 2019. In that year, the company reported total emissions of approximately 1,038,000,000 kg CO2e, broken down into Scope 1 emissions of about 359,000,000 kg CO2e, Scope 2 emissions of around 306,000,000 kg CO2e, and Scope 3 emissions totalling approximately 373,000,000 kg CO2e. Notably, within Scope 3, emissions from purchased goods and services accounted for about 127,000,000 kg CO2e, while waste generated in operations contributed approximately 84,000,000 kg CO2e. Despite these substantial figures, Bioreliance has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction strategies suggests a need for further commitment to climate action within the industry context. As the global focus on sustainability intensifies, it is crucial for companies like Bioreliance to establish clear climate commitments and reduction goals to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|
| Scope 1 | 378,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 404,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 426,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bioreliance is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
